IMMUNOMODULATORY MEDICATIONS AND OUTCOMES OF PATIENTS WITH PRE-EXISTING RHEUMATOID ARTHRITIS USING IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCER

被引：0

作者：

Arabelovic, S. ^{[1
]}

Mccarter, K. ^{[2
]}

Wolfgang, T. ^{[1
]}

Wang, X. ^{[1
]}

Yoshida, K. ^{[1
]}

Banasiak, E. ^{[1
]}

Qian, G. ^{[1
]}

Kowalski, E. ^{[1
]}

Vanni, K. ^{[1
]}

Leboeuf, N. ^{[3
]}

Buchbinder, E. ^{[4
]}

Gedmintas, L. ^{[1
]}

Macfarlane, L. ^{[1
]}

Rao, D. ^{[1
]}

Shadick, N. ^{[1
]}

Gravallese, E. ^{[1
]}

Sparks, J. ^{[1
]}

机构：

[1] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA USA

[3] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA

[4] Dana Farber Canc Inst, Dept Med, Boston, MA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Malignancy; Rheumatoid arthritis;

D O I：

10.1136/annrheumdis-2023-eular.2072

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0028

引用

页码：18 / 19

页数：2

共 50 条

[41] Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
Gonugunta, Amrit S.
Wang, Yiqing
Sheffield, Thomas
Lu, Rong
Ali, Sadia
Fattah, Farjana J.
Xie, Donglu
Cai, Jennifer
Xie, Yang
Gerber, David E.
Von Itzstein, Mitchell S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 137 - 137
[42] Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Carroll, Emily
Leiter, Amanda
Brooks, Danielle
Ben Shimol, Jennifer
Eisenberg, Elliot
Galsky, Matthew
Gallagher, Emily
Wiesendanger, Margrit
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[43] Adverse events following immune checkpoint inhibitors by pre-existing comorbidities and polypharmacy among patients with lung cancer: A population-based study
Nikita, Nikita
Sharma, Swapnil
Shaver, Amy
Gandhi, Krupa
Keith, Scott
Yang, Christopher
Gordon, Sarah
Grace Lu-Yao
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (12)
[44] Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID
Amiot, Aurelien
Laharie, David
Malamut, Georgia
Serrero, Melanie
Poullenot, Florian
DIGESTIVE AND LIVER DISEASE, 2022, 54 (09) : 1162 - 1167
[45] Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
Noseda, Roberta
Ruinelli, Lorenzo
van der Gaag, Linda C.
Ceschi, Alessandro
CANCERS, 2020, 12 (11) : 1 - 15
[46] Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases
Meserve, Joseph
Facciorusso, Antonio
Holmer, Ariela K.
Annese, Vito
Sandborn, William J.
Singh, Siddharth
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (03) : 374 - 382
[47] Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Bruce, Alana
Long, Georgina V.
Menzies, Alexander M.
Fernandes, Brian
Joshua, Fredrick
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1502 - 1505
[48] Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data
Calvo, Virginia
Fernandez, Marta Andres
Collazo-Lorduy, Ana
Franco, Fernando
Nunez, Beatriz
Provencio, Mariano
LUNG CANCER MANAGEMENT, 2021, 10 (04)
[49] Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Sparks, Jeffrey A.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2024, 50 (02) : 147 - 159
[50] Safety of immune checkpoint inhibitors in patients with advanced malignancy complicated with rheumatoid arthritis
Kudo, Keita
Nakajima, Saki
Uejima, Shigeya
Horiuchi, Tetsuya
Nakanishi, Fumihiko
Utunomiya, Takuhide
Kakiuchi, Mai
Yamaguchi, Mami
Ohshima, Shiro
ANNALS OF ONCOLOGY, 2021, 32 : S301 - S301

← 1 2 3 4 5 →